Cogent Biosciences’ treatment of mastocytosis was granted orphan status by the FDA, according to a posting to the agency’s website. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences price target lowered to $23 from $24 at Needham
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
- Cogent Biosciences reports Q4 EPS (56c), consensus (52c)
- Needham biotech analysts to hold an analyst/industry conference call